HIV Testing at One Month Post-Exposure
At approximately one month (4–6 weeks) after HIV exposure, perform both a laboratory-based HIV antigen/antibody (Ag/Ab) combination test AND a diagnostic HIV nucleic acid test (NAT). 1111
Testing Algorithm at ~30 Days Post-Exposure
The 2025 CDC guidelines establish a clear dual-testing approach for interim HIV screening:
- Laboratory-based HIV Ag/Ab combination immunoassay (4th generation test)
- Diagnostic HIV NAT (nucleic acid test/RNA test)
Both tests must be performed together at the 4–6 week timepoint 1111. This represents standard of care and ensures detection during the critical window period when antibody responses may still be developing but viral RNA is detectable.
Important Exception: When Testing May Be Deferred
HIV testing at 4–6 weeks may be deferred if the patient:
This exception recognizes that perfect adherence to early-initiated prophylaxis provides sufficient protection to delay interim testing.
Follow-Up Testing Requirements
Final HIV testing must occur at 12 weeks (3 months) post-exposure using:
This 12-week timepoint represents the definitive window for excluding HIV infection, as even 4th generation Ag/Ab tests have window periods extending to approximately 42–44 days at the 99th percentile 23.
Critical Pitfalls to Avoid
Do not rely on rapid/point-of-care tests alone at one month. While 4th generation rapid tests have improved sensitivity, they still demonstrate reduced performance in pre-seroconversion samples (66.7–81.5% sensitivity) 4. Laboratory-based testing combined with NAT provides superior detection during this critical window.
Do not assume a negative test at one month definitively excludes HIV. The median window period for 4th generation tests is 18 days, but the interquartile range extends to 24 days, and some individuals may take longer to seroconvert 3. The dual-testing approach (Ag/Ab + NAT) at 4–6 weeks captures most infections, but the 12-week final test remains essential.
Special consideration for long-acting injectable PrEP users: If the patient had long-acting injectable PrEP exposure within the past 12 months, NAT testing is particularly critical at all timepoints, as antiretroviral exposure can delay or suppress antibody responses 1111.
Rationale for Dual Testing
The combination of Ag/Ab and NAT testing addresses different phases of HIV infection:
- NAT detects viral RNA as early as 10–12 days post-infection (after the eclipse period) 2
- Ag/Ab tests detect p24 antigen (appearing around 2 weeks) and antibodies (appearing around 3–4 weeks) 25
At the one-month mark, most patients will have detectable antibodies, but those in late acute infection or with delayed seroconversion benefit from the added sensitivity of NAT 25.